Emergent BioSolutions reported Q3 2024 revenues of $293.8 million, up 9% year-over-year. Net income was $114.8 million compared to a net loss of $263.4 million in Q3 2023. The company's MCM Products segment saw strong growth with revenues up 62% to $174.2 million.Emergent made significant progress in improving its financial position during the quarter. It entered into a new $250 million Term Loan Agreement and a $100 million Revolving Credit Agreement. The company also generated cash through asset sales, including $75 million from the sale of RSDL and $35 million from the sale of its Baltimore-Camden facility.Looking ahead, Emergent believes it has alleviated substantial doubt about its ability to continue as a going concern. With $149.9 million in cash and $100 million available under its credit facility as of September 30, the company expects its liquidity sources to be adequate to fund operations for at least the next 12 months. However, Emergent noted ongoing risks and uncertainties related to product sales and development programs.

Emergent BioSolutions reported Q3 2024 revenues of $293.8 million, up 9% year-over-year. Net income was $114.8 million compared to a net loss of $263.4 million in Q3 2023. The company's MCM Products segment saw strong growth with revenues up 62% to $174.2 million.Emergent made significant progress in improving its financial position during the quarter. It entered into a new $250 million Term Loan Agreement and a $100 million Revolving Credit Agreement. The company also generated cash through asset sales, including $75 million from the sale of RSDL and $35 million from the sale of its Baltimore-Camden facility.Looking ahead, Emergent believes it has alleviated substantial doubt about its ability to continue as a going concern. With $149.9 million in cash and $100 million available under its credit facility as of September 30, the company expects its liquidity sources to be adequate to fund operations for at least the next 12 months. However, Emergent noted ongoing risks and uncertainties related to product sales and development programs.